The Department of Defense (DoD) is offering the Gulf War Illness Investigator-Initiated Research Award to support research focusing on the complex symptoms of Gulf War Illness (GWI). This grant aims to improve GWI definition and diagnosis, characterize symptoms, and deepen understanding of its pathobiology. It encourages basic through clinical studies to identify objective measures (e.g., biomarkers), elucidate treatment targets, or understand chronic effects of neurotoxic exposures. Areas of interest include CNS, neuroinflammatory, autonomic, neuroendocrine, immune, GI, genetic, respiratory, and sexual dysfunction. The award supports proof of principle, ADME studies, toxicology testing, and preclinical development of non-pharmacological interventions, promoting new ideas to ultimately benefit ill Gulf War veterans. Clinical trials are not permitted, but retrospective or other non-interventional designs are acceptable.
Opportunity ID: 234618
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-13-GWIRP-IIRA |
| Funding Opportunity Title: | DoD Gulf War Illness Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 3 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 14, 2013 |
| Last Updated Date: | Aug 21, 2013 |
| Original Closing Date for Applications: | Sep 18, 2013 |
| Current Closing Date for Applications: | Sep 18, 2013 |
| Archive Date: | Oct 18, 2013 |
| Estimated Total Program Funding: | $2,880,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Investigator-Initiated Research Award was first offered in FY06. Since then, 156 Investigator-Initiated Research Award applications have been received, and 42 have been recommended for funding.The Investigator-Initiated Research Award (IIRA) supports research focusing on the complex of symptoms known as Gulf War Illness, improving its definition and diagnosis, characterizing disease symptoms, and better understanding its pathobiology. It is intended to encourage basic through clinical research aimed at identification of objective measures to distinguish ill from healthy veterans (e.g., biomarkers), elucidate potential treatment targets for GWI, or improve understanding of the pathobiology underlying GWI symptoms. In addition, studies that characterize chronic effects of neurotoxic exposures at dosage comparable to that encountered during the Gulf War are acceptable. Particular areas of interest include research on objective indicators of biological processes or abnormalities in GWI associated with: Central nervous system structure and function, in particular, the role of glial cells, astrocytes, and microglia in GWI symptomatology Central neuroinflammatory processes Autonomic nervous system function Neuroendocrine measures Immune parameters/Indicators of chronic infection Gastrointestinal complaints/symptoms Genetic, genomic, proteomic, or metabolic characteristics Respiratory symptoms Sexual dysfunctionThe IIRA provides investigators a mechanism to establish proof of principle for further development in future studies. The IIRA can also be used for testing of GWI-targeted pharmacologic agents in Adsorption, Distribution, Metabolism, Excretion (ADME) studies, and toxicology testing, including Investigational New Drug (IND)-enabling pharmacology/ toxicology testing. Preclinical development of non-pharmacological interventions is also acceptable.The IIRA is designed to promote new ideas in GWI research. Applications are not required to include preliminary data; however, preliminary data may be used to support the objectives of an application. These data are not required to have come from the GWI research field. Applications not supported by preliminary data should be based on a sound scientific rationale and may reflect clinical observations or seek to evaluate GWI discoveries made in relation to other chronic multi-symptom illnesses. Regardless of the approach, the focus should be clearly on ill Gulf War veterans. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the projects potential impact on GWI.Applicants proposing clinical research must provide a published case definition they intend to use to define their GWI population. Any case definition must recognize the multi-symptom nature of GWI. PIs proposing studies using animal models should focus on long-term and latent effects of toxic exposures to closely represent the current status of GWI patients. Note: The 2008 report of the Research Advisory Committee on Gulf War Veterans Illnesses, Gulf War Illness and the Health of Gulf War Veterans, provides information on GWI case definitions (pp. 29-30, p. 57), previous treatment research in Gulf War veterans (pp. 36-39), and treatment research related to other multi-symptom conditions (pp. 285-287). The report can be found online at: http://www1.va.gov/RAC-GWVI/.Research involving human subjects is permitted under this funding opportunity but is restricted to studies without clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention or other) is tested on a human subject for ameasurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. For more information on clinical research, see Human Subject Resource Document athttps://cdmrp.org/Program_Announcements_and_Forms/.PIs interested in applying for funding for a clinical trial should utilize either the Innovative Treatment Evaluation Award or the Clinical Trial Award mechanisms (for information about those mechanisms, see http://cdmrp.army.mil/gwirp). Retrospective studies or other non-interventional designs are acceptable under the IIRA. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
| The purpose of this modification is to correct information regarding the number of citations allowed. | Aug 21, 2013 | |
| Aug 21, 2013 |
DISPLAYING: Synopsis 2
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-13-GWIRP-IIRA |
| Funding Opportunity Title: | DoD Gulf War Illness Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 3 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 2 |
| Posted Date: | May 14, 2013 |
| Last Updated Date: | Aug 21, 2013 |
| Original Closing Date for Applications: | Sep 18, 2013 |
| Current Closing Date for Applications: | Sep 18, 2013 |
| Archive Date: | Oct 18, 2013 |
| Estimated Total Program Funding: | $2,880,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Investigator-Initiated Research Award was first offered in FY06. Since then, 156 Investigator-Initiated Research Award applications have been received, and 42 have been recommended for funding.The Investigator-Initiated Research Award (IIRA) supports research focusing on the complex of symptoms known as Gulf War Illness, improving its definition and diagnosis, characterizing disease symptoms, and better understanding its pathobiology. It is intended to encourage basic through clinical research aimed at identification of objective measures to distinguish ill from healthy veterans (e.g., biomarkers), elucidate potential treatment targets for GWI, or improve understanding of the pathobiology underlying GWI symptoms. In addition, studies that characterize chronic effects of neurotoxic exposures at dosage comparable to that encountered during the Gulf War are acceptable. Particular areas of interest include research on objective indicators of biological processes or abnormalities in GWI associated with: Central nervous system structure and function, in particular, the role of glial cells, astrocytes, and microglia in GWI symptomatology Central neuroinflammatory processes Autonomic nervous system function Neuroendocrine measures Immune parameters/Indicators of chronic infection Gastrointestinal complaints/symptoms Genetic, genomic, proteomic, or metabolic characteristics Respiratory symptoms Sexual dysfunctionThe IIRA provides investigators a mechanism to establish proof of principle for further development in future studies. The IIRA can also be used for testing of GWI-targeted pharmacologic agents in Adsorption, Distribution, Metabolism, Excretion (ADME) studies, and toxicology testing, including Investigational New Drug (IND)-enabling pharmacology/ toxicology testing. Preclinical development of non-pharmacological interventions is also acceptable.The IIRA is designed to promote new ideas in GWI research. Applications are not required to include preliminary data; however, preliminary data may be used to support the objectives of an application. These data are not required to have come from the GWI research field. Applications not supported by preliminary data should be based on a sound scientific rationale and may reflect clinical observations or seek to evaluate GWI discoveries made in relation to other chronic multi-symptom illnesses. Regardless of the approach, the focus should be clearly on ill Gulf War veterans. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the projects potential impact on GWI.Applicants proposing clinical research must provide a published case definition they intend to use to define their GWI population. Any case definition must recognize the multi-symptom nature of GWI. PIs proposing studies using animal models should focus on long-term and latent effects of toxic exposures to closely represent the current status of GWI patients. Note: The 2008 report of the Research Advisory Committee on Gulf War Veterans Illnesses, Gulf War Illness and the Health of Gulf War Veterans, provides information on GWI case definitions (pp. 29-30, p. 57), previous treatment research in Gulf War veterans (pp. 36-39), and treatment research related to other multi-symptom conditions (pp. 285-287). The report can be found online at: http://www1.va.gov/RAC-GWVI/.Research involving human subjects is permitted under this funding opportunity but is restricted to studies without clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention or other) is tested on a human subject for ameasurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. For more information on clinical research, see Human Subject Resource Document athttps://cdmrp.org/Program_Announcements_and_Forms/.PIs interested in applying for funding for a clinical trial should utilize either the Innovative Treatment Evaluation Award or the Clinical Trial Award mechanisms (for information about those mechanisms, see http://cdmrp.army.mil/gwirp). Retrospective studies or other non-interventional designs are acceptable under the IIRA. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
DISPLAYING: Synopsis 1
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | W81XWH-13-GWIRP-IIRA |
| Funding Opportunity Title: | DoD Gulf War Illness Investigator-Initiated Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 3 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Aug 21, 2013 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | – |
| Current Closing Date for Applications: | Sep 18, 2013 |
| Archive Date: | Oct 18, 2013 |
| Estimated Total Program Funding: | $2,880,000 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: | The GWIRP Investigator-Initiated Research Award was first offered in FY06. Since then, 156 Investigator-Initiated Research Award applications have been received, and 42 have been recommended for funding. The Investigator-Initiated Research Award (IIRA) supports research focusing on the complex of symptoms known as Gulf War Illness, improving its definition and diagnosis, characterizing disease symptoms, and better understanding its pathobiology. It is intended to encourage basic through clinical research aimed at identification of objective measures to distinguish ill from healthy veterans (e.g., biomarkers), elucidate potential treatment targets for GWI, or improve understanding of the pathobiology underlying GWI symptoms. In addition, studies that characterize chronic effects of neurotoxic exposures at dosage comparable to that encountered during the Gulf War are acceptable. Particular areas of interest include research on objective indicators of biological processes or abnormalities in GWI associated with: Central nervous system structure and function, in particular, the role of glial cells, astrocytes, and microglia in GWI symptomatology Central neuroinflammatory processes Autonomic nervous system function Neuroendocrine measures Immune parameters/Indicators of chronic infection Gastrointestinal complaints/symptoms Genetic, genomic, proteomic, or metabolic characteristics Respiratory symptoms Sexual dysfunction The IIRA provides investigators a mechanism to establish proof of principle for further development in future studies. The IIRA can also be used for testing of GWI-targeted pharmacologic agents in Adsorption, Distribution, Metabolism, Excretion (ADME) studies, and toxicology testing, including Investigational New Drug (IND)-enabling pharmacology/ toxicology testing. Preclinical development of non-pharmacological interventions is also acceptable. The IIRA is designed to promote new ideas in GWI research. Applications are not required to include preliminary data; however, preliminary data may be used to support the objectives of an application. These data are not required to have come from the GWI research field. Applications not supported by preliminary data should be based on a sound scientific rationale and may reflect clinical observations or seek to evaluate GWI discoveries made in relation to other chronic multi-symptom illnesses. Regardless of the approach, the focus should be clearly on ill Gulf War veterans. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate the projects potential impact on GWI. Applicants proposing clinical research must provide a published case definition they intend to use to define their GWI population. Any case definition must recognize the multi-symptom nature of GWI. PIs proposing studies using animal models should focus on long-term and latent effects of toxic exposures to closely represent the current status of GWI patients. Note: The 2008 report of the Research Advisory Committee on Gulf War Veterans Illnesses, Gulf War Illness and the Health of Gulf War Veterans, provides information on GWI case definitions (pp. 29-30, p. 57), previous treatment research in Gulf War veterans (pp. 36-39), and treatment research related to other multi-symptom conditions (pp. 285-287). The report can be found online at: http://www1.va.gov/RAC-GWVI/. Research involving human subjects is permitted under this funding opportunity but is restricted to studies without clinical trials. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. For more information on clinical research, see Human Subject Resource Document at https://cdmrp.org/Program_Announcements_and_Forms/. PIs interested in applying for funding for a clinical trial should utilize either the Innovative Treatment Evaluation Award or the Clinical Trial Award mechanisms (for information about those mechanisms, see http://cdmrp.army.mil/gwirp). Retrospective studies or other non-interventional designs are acceptable under the IIRA. |
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
301-682-5507 Email:help@cdmrp.org |
Related Documents
Folder 234618 Full Announcement-1 -> gwirp fy13 iira pa_gg_21aug13.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk 301-682-5507 Email: help@cdmrp.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00177835 | May 14, 2013 | Sep 18, 2013 | View |
Package 1
Mandatory forms
234618 RR_SF424_1_2-1.2.pdf
234618 PerformanceSite_1_4-1.4.pdf
234618 RR_Budget-1.1.pdf
234618 RR_KeyPersonExpanded_1_2-1.2.pdf
Optional forms
234618 RR_SubawardBudget30-1.2.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
